TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19367116

Group type: EXPERIMENTAL
Intervention: Probiotics (various strains such as Bifidobacterium, Lactobacillus, and Lactococcus) administered during the perinatal period
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 16429250

Group type: EXPERIMENTAL
Intervention: SMART debriefing
Number of subjects: 51
Study: 15110921

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (5 or 10 mg, p.o.)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: CRH stimulation (1 g/kg i.v.)
Number of subjects: 16
Study: 11128916

Group type: EXPERIMENTAL
Intervention: Coronally advanced flap (CAF) with enamel matrix derivative (EMD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Coronally advanced flap (CAF) without enamel matrix derivative (EMD)
Number of subjects: 12
Study: 9282767

Group type: EXPERIMENTAL
Intervention: Veress needle technique in the umbilicus
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Upper left quadrant insertion
Number of subjects: 75

Group type: COMPARATOR
Intervention: Direct insertion with a disposable trocar in the umbilicus without pneumoperitoneum
Number of subjects: 75
Study: 8463575

Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg on days 1 and 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Mifepristone
Number of subjects: 120
Study: 2939218

Group type: EXPERIMENTAL
Intervention: Ketanserin (K), 40 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Metoprolol (M), 200 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketanserin (K)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ketanserin (K) plus Metoprolol (M)
Number of subjects: 24
Study: 31895236

Group type: EXPERIMENTAL
Intervention: Arthroscopic Bankart repair (ABR)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Arthroscopic washout (AWO)
Number of subjects: 88
Study: 29447347

Group type: EXPERIMENTAL
Intervention: 6-month lifestyle intervention
Number of subjects: 184

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 184
Study: 27966652

Group type: EXPERIMENTAL
Intervention: Transcatheter PFO closure
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no PFO closure)
Number of subjects: 258
Study: 23588488

Group type: EXPERIMENTAL
Intervention: Foam rolling
Number of subjects: 26

Group type: COMPARATOR
Intervention: Planking
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Foam rolling and Planking
Number of subjects: 26
Study: 22246011

Group type: EXPERIMENTAL
Intervention: Carotid angioplasty stent placement (CAS)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 182
Study: 20002596

Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Milnacipran 100 mg/day (re-randomized from placebo or milnacipran 100 mg/day)
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Milnacipran 200 mg/day (for patients re-randomized from placebo)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo (initial treatment)
Number of subjects: 449
Study: 18754195

Group type: EXPERIMENTAL
Intervention: Ibuprofen-releasing foam dressing (Biatain Ibu, ColoplastA/S)
Number of subjects: 853

Group type: COMPARATOR
Intervention: Local best practice
Number of subjects: 853

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 853
Study: 15286005

Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg or 10 mg/kg every four or eight weeks)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Methotrexate alone
Number of subjects: 428
Study: 12799626

Group type: EXPERIMENTAL
Intervention: Darbepoetin alpha QW (0.5, 1.0, 2.25, or 4.5 micro g kg(‐1) week(‐1) for 12 weeks)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Darbepoetin alpha Q3W (6.75 micro g kg(‐1) for 12 weeks)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Darbepoetin alpha Q4W (6.75 or 10.0 micro g kg(‐1) for 12 weeks)
Number of subjects: 188
Study: 11382272

Group type: EXPERIMENTAL
Intervention: Audiovisual distraction
Number of subjects: 50

Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 50
Study: 9780257

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 500 mg orally twice daily for 7 days
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 8195451

Group type: EXPERIMENTAL
Intervention: Clonazepam (mean dose 2.2 mg, SD 0.7 mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 3658286

Group type: EXPERIMENTAL
Intervention: Doxycycline 400 mg
Number of subjects: 800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study: 30700591

Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 132

Group type: COMPARATOR
Intervention: Stretching/toning
Number of subjects: 132
Study: 28328526

Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 IU single oral dose)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study: 26401670

Group type: EXPERIMENTAL
Intervention: Patient mouth mask worn by the patient
Number of subjects: 60

Group type: COMPARATOR
Intervention: No patient mouth mask worn
Number of subjects: 60
Study: 24034569

Group type: EXPERIMENTAL
Intervention: High-dose Asiatic plantain extract (20 g/80 mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 21964893

Group type: EXPERIMENTAL
Intervention: Bevacizumab containing chemotherapy
Number of subjects: 0
Study: 19759073

Group type: EXPERIMENTAL
Intervention: Parents Plus Children's Programme (PPCP)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 74
Study: 17052276

Group type: EXPERIMENTAL
Intervention: PEG‐IFN (180 microg sc weekly) and standard dose of RBV (1000/1200 mg po daily, STD)
Number of subjects: 124

Group type: COMPARATOR
Intervention: PEG‐IFN (180 microg sc weekly) and low‐dose of RBV (600/800 mg po daily, LOW)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: PEG‐IFN/STD RBV
Number of subjects: 124

Group type: COMPARATOR
Intervention: PEG‐IFN/LOW RBV
Number of subjects: 124
Study: 12588538

Group type: EXPERIMENTAL
Intervention: Investigational anticancer drugs
Number of subjects: 28

Group type: COMPARATOR
Intervention: Earlier phases of investigational anticancer drugs
Number of subjects: 28
Study: 10960412

Group type: EXPERIMENTAL
Intervention: Hyperbaric air (Group A)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Hyperbaric oxygen (Group O)
Number of subjects: 36
Study: 9249272

Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (NaCl 0.9%)
Number of subjects: 25
Study: 8445198

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone given within 8 hours of spinal cord injury
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30968729

Group type: EXPERIMENTAL
Intervention: Nivolumab (PD-1 blockade)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 27209422

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral treatment (CBT) in the form of exposure and response prevention, 14 weekly sessions
Number of subjects: 241
Study: 26159101

Group type: EXPERIMENTAL
Intervention: Acetazolamide plus supervised diet
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo plus supervised diet
Number of subjects: 165
Study: 24660585

Group type: EXPERIMENTAL
Intervention: Yishenjiangzhuo granules (YJG)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control
Number of subjects: 53
Study: 21677432

Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control
Number of subjects: 100
Study: 18714248

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 24

Group type: COMPARATOR
Intervention: No-stretch control condition
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: All stretching conditions (static and ballistic)
Number of subjects: 24
Study: 16520033

Group type: EXPERIMENTAL
Intervention: 60 mg/m2 every 6 weeks (ARM A)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 every 4 weeks (ARM B)
Number of subjects: 116
Study: 14739717

Group type: EXPERIMENTAL
Intervention: Dofetilide
Number of subjects: 506

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 506
Study: 10714017

Group type: EXPERIMENTAL
Intervention: Nicorandil pretreatment (0.3 mg/kg) 30 minutes before aortic cross clamping
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (not pretreated with nicorandil)
Number of subjects: 40
Study: 8959996

Group type: EXPERIMENTAL
Intervention: 50 mg riluzole
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: 100 mg riluzole
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: 200 mg riluzole
Number of subjects: 959

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 959

Group type: EXPERIMENTAL
Intervention: Riluzole (any dose)
Number of subjects: 959
Study: 1552399

Group type: EXPERIMENTAL
Intervention: Partial plasma exchange transfusion (PPET)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Control group (normal viscosity)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Symptomatic hyperviscosity
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Asymptomatic hyperviscosity
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: PPET
Number of subjects: 71
Study: 4088224

Group type: EXPERIMENTAL
Intervention: Splenectomy (+)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Splenectomy (−)
Number of subjects: 0
Study: 29533998

Group type: EXPERIMENTAL
Intervention: Daily vitamin D therapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: Depot vitamin D therapy
Number of subjects: 151
Study: 25782919

Group type: EXPERIMENTAL
Intervention: Ropivacaine (0.25%, 40 mL)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control (0.9% saline, 40 mL)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study: 24447501

Group type: EXPERIMENTAL
Intervention: Levosimendan (6 μg/kg loading dose followed by 0.1 μg/kg/min infusion for 24 hours)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard inotropic therapy
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 128
Study: 23304974

Group type: EXPERIMENTAL
Intervention: Subgroup 1: diamond disk followed by a fine Sof-lex disc
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Subgroup 4: diamond disk and chemical stripping using 37% orthophosphoric acid in conjunction with a fine 3M finishing strip
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All proximal stripping and polishing methods
Number of subjects: 60

Group type: COMPARATOR
Intervention: Subgroup 5 (control): no stripping nor polishing
Number of subjects: 60
Study: 20150300

Group type: EXPERIMENTAL
Intervention: Treatment of mild GDM during pregnancy
Number of subjects: 199

Group type: COMPARATOR
Intervention: Routine care control group
Number of subjects: 199
Study: 16769748

Group type: EXPERIMENTAL
Intervention: Clomifene citrate plus metformin
Number of subjects: 228

Group type: COMPARATOR
Intervention: Clomifene citrate plus placebo
Number of subjects: 228
Study: 14992910

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary bypass established through the femoral artery and vein before sternal reentry (Group 1, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Cardiopulmonary bypass performed after sternal reentry (Group 2, n = 100)
Number of subjects: 200
Study: 11547841

Group type: EXPERIMENTAL
Intervention: Milk supplementation (50 g of milk powder containing 800 mg of calcium per day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 200
Study: 9211762

Group type: EXPERIMENTAL
Intervention: Propionyl-L-carnitine (PLC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 7584268

Group type: EXPERIMENTAL
Intervention: Priming effects through category fluency task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Typical category instances as targets
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Atypical category instances as targets
Number of subjects: 0
Study: 3319639

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31917621

Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa (380 U/kg/d for 14 days by intravenous drip infusion)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Thrombomodulin alfa
Number of subjects: 82
Study: 30503879

Group type: EXPERIMENTAL
Intervention: Pharmacist-led intervention
Number of subjects: 1463
Study: 29282142

Group type: EXPERIMENTAL
Intervention: PRIME complex intervention (recruitment co-ordinator, bespoke stroke audit data exports, follow-up review after 6 months)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (before allocation to the PRIME complex intervention)
Number of subjects: 72
Study: 25722979

Group type: EXPERIMENTAL
Intervention: Clipping
Number of subjects: 156

Group type: COMPARATOR
Intervention: Nonclipping
Number of subjects: 156
Study: 24457205

Group type: EXPERIMENTAL
Intervention: Weight loss programme delivered by community coaching staff in 12 sessions held every week
Number of subjects: 747

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 747
Study: 22375955

Group type: EXPERIMENTAL
Intervention: Immersion tub bathing
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sponge bathing
Number of subjects: 100
Study: 19222416

Group type: EXPERIMENTAL
Intervention: EUS-guided coeliac plexus block (EUS-CPB)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Percutaneous fluoroscopy guided coeliac plexus block (PCFG-CPB)
Number of subjects: 56
Study: 17692438

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) route with 3, 6, or 9 microg of vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular (IM) route with 15 microg of vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) route
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intramuscular (IM) route
Number of subjects: 0
Study: 15640721

Group type: EXPERIMENTAL
Intervention: Exercise training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pragmatic alternatives
Number of subjects: 0
Study: 12373440

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg alcohol
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 3.3% THC
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0.25 g/kg alcohol
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0 g/kg alcohol
Number of subjects: 12

Group type: COMPARATOR
Intervention: 0% THC
Number of subjects: 12

Group type: COMPARATOR
Intervention: 1.75% THC
Number of subjects: 12
Study: 10425052

Group type: EXPERIMENTAL
Intervention: Pap tests reported as CIN I
Number of subjects: 449

Group type: COMPARATOR
Intervention: First review
Number of subjects: 449

Group type: COMPARATOR
Intervention: Second review
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Final classification
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Undercalls
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Overcalls
Number of subjects: 449
Study: 8525125

Group type: EXPERIMENTAL
Intervention: Hypoxia (FIO2 = 0.14)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normoxia (room air)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Hyperoxia (FIO2 = 0.70)
Number of subjects: 6
Study: 2255416

Group type: EXPERIMENTAL
Intervention: Thymopentin
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no Thymopentin)
Number of subjects: 46
Study: 6997212

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulfamethoxazole
Number of subjects: 17
Study: 31134488

Group type: EXPERIMENTAL
Intervention: Trastuzumab and/or lapatinib for 1 year
Number of subjects: 6273

Group type: COMPARATOR
Intervention: Control group (HR-negative tumors)
Number of subjects: 6273
Study: 28035589

Group type: EXPERIMENTAL
Intervention: Caspofungin 100 mg loading dose followed by 50 mg maintenance dose for patients with total body weight of ≤80 kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caspofungin 70 mg maintenance dose for patients with total body weight of >80 kg
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caspofungin CRRT clearance (CL) for CVVH
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caspofungin CRRT clearance (CL) for CVVHDF
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Caspofungin pharmacokinetic parameters
Number of subjects: 9
Study: 25297372

Group type: EXPERIMENTAL
Intervention: In-house biochemistry analysers
Number of subjects: 94

Group type: COMPARATOR
Intervention: Commercial laboratory analyser
Number of subjects: 94
Study: 23375819

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 3 g/d
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous cyclophosphamide (0.5‐1 g/m²)
Number of subjects: 32
Study: 21516030

Group type: EXPERIMENTAL
Intervention: tesamorelin (2 mg subcutaneously daily for 26 weeks)
Number of subjects: 410

Group type: COMPARATOR
Intervention: placebo (subcutaneously daily for 26 weeks)
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: tesamorelin
Number of subjects: 410
Study: 19050966

Group type: EXPERIMENTAL
Intervention: Orientation with additional Prolene suture placed by the surgeon on one side
Number of subjects: 122
Study: 17279300

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin 1 g/day and tinidazole 15 mg/kg/day for 4 weeks
Number of subjects: 16

Group type: COMPARATOR
Intervention: Mesalamine (4 g/day oral, 8 g/day enema, or 1 g/day suppository)
Number of subjects: 16
Study: 15484217

Group type: EXPERIMENTAL
Intervention: Low-dose suramin
Number of subjects: 385

Group type: COMPARATOR
Intervention: Intermediate-dose suramin
Number of subjects: 385

Group type: COMPARATOR
Intervention: High-dose suramin
Number of subjects: 385

Group type: EXPERIMENTAL
Intervention: All groups post-treatment
Number of subjects: 385
Study: 11939497

Group type: EXPERIMENTAL
Intervention: Hypothermia
Number of subjects: 102

Group type: COMPARATOR
Intervention: Normothermia
Number of subjects: 102
Study: 9879787

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 8028755

Group type: EXPERIMENTAL
Intervention: carbocalcitonin + arginine-lysine-lactose combination
Number of subjects: 40

Group type: COMPARATOR
Intervention: carbocalcitonin alone (40 UMRC day i.m. on alternative days)
Number of subjects: 40
Study: 2653110

Group type: EXPERIMENTAL
Intervention: Testosterone-undecanoate 120 mg per os for 100 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 887645

Group type: EXPERIMENTAL
Intervention: 300 IU daily of synthetic oxytocin
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 600 IU daily of synthetic oxytocin
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 31720836

Group type: EXPERIMENTAL
Intervention: Orthokeratology lenses
Number of subjects: 50
Study: 31561192

Group type: EXPERIMENTAL
Intervention: Real-time medication monitoring pill bottle linked to an HIV self-management app
Number of subjects: 38
Study: 28327114

Group type: EXPERIMENTAL
Intervention: Unilateral laminotomy with crossover
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Bilateral laminotomy
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: Spinous process osteotomy
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: All techniques
Number of subjects: 465
Study: 1445478

Group type: EXPERIMENTAL
Intervention: Loratadine 10 mg q.d.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Hydroxyzine 25 mg t.i.d.
Number of subjects: 203

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 203
Study: 22048237

Group type: EXPERIMENTAL
Intervention: Selumetinib (100 mg orally twice daily in 28-day cycles)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Temozolomide (200 mg/m2/day for 5 days, then 23 days off-treatment)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Selumetinib (in patients with BRAF mutations)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Temozolomide (in patients with BRAF mutations)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Selumetinib
Number of subjects: 200

Group type: COMPARATOR
Intervention: Temozolomide
Number of subjects: 200
Study: 20413076

Group type: EXPERIMENTAL
Intervention: HPV-16/18 AS04-adjuvanted vaccine
Number of subjects: 2067

Group type: COMPARATOR
Intervention: Hepatitis A virus vaccine (control)
Number of subjects: 2067
Study: 18396374

Group type: EXPERIMENTAL
Intervention: Ibuprofen 800 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Experimental inflammation (UVB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Noxious heat
Number of subjects: 0
Study: 16433603

Group type: EXPERIMENTAL
Intervention: Biogel Indicator Glove System (indicator gloves)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Latex indicator gloves
Number of subjects: 25

Group type: COMPARATOR
Intervention: Worst-performing latex gloves
Number of subjects: 25

Group type: COMPARATOR
Intervention: Worst-performing synthetic gloves
Number of subjects: 25

Group type: COMPARATOR
Intervention: Non-indicator gloves
Number of subjects: 25
Study: 12629088

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy
Number of subjects: 451

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 451
Study: 10597132

Group type: EXPERIMENTAL
Intervention: Transurethral vaporization of the prostate (TUVP)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 78
Study: 8743100

Group type: EXPERIMENTAL
Intervention: Storage at -20 degrees C for 6 months
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Storage at -20 degrees C for up to 46 months
Number of subjects: 85
Study: 1836986

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg/day
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cilazapril 5.0 mg/day
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Cilazapril 10.0 mg/day
Number of subjects: 235

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 235